ActivBiotics Inc., of Lexington, Mass., appointed Glenn Kazo chief business officer.

Aegera Therapeutics Inc., of Montreal, appointed William Peters and Lennie Ryer to its board.

Anacor Pharmaceuticals Inc., of Palo Alto, Calif., appointed Karen Martell vice president of business development.

Avera Pharmaceuticals Inc., of Irvine, Calif., appointed Jeffrey McKelvy president and CEO.

Boston Biomedical Research Institute in Watertown, Mass., appointed Terence McGowan director of institutional advancement.

Catalyst Pharmaceutical Partners, of Coral Gables, Fla., appointed Jack Weinstein chief financial officer.

Corautus Genetics Inc., of Atlanta, formed a steering committee co-chaired by Douglas Losordo and Richard Kuntz. Members are Timothy Henry, Robert Simari and Byron Williams.

Cyberkinetics Neurotechnology Systems Inc., of Foxborough, Mass., appointed Daniel Geffken to its board.

Cytomedix Inc., of Rockville, Md., appointed Eduardo March director of quality assurance and regulatory affairs.

Gartmore Global Investments, of Conshohocken, Pa., appointed Andrew Kauth health care equities analyst.

Inex Pharmaceuticals Corp., of Vancouver, British Columbia, appointed Timothy Ruane senior vice president, corporate development.

Isis Pharmaceuticals Inc., of Carlsbad, Calif., appointed Michael Treble CEO of its Ibis program.

Kemia Inc., of San Diego, appointed Alison Pilgrim chief medical officer and Bryan Jones vice president of business development.

Korn/Ferry International, of Redwood City, Calif., appointed Erik Lundh client partner in the biotechnology/life sciences practice.

Lumenis Ltd., of Yokneam, Israel, appointed Ronald Salvagio to its board.

Morphotek Inc., of Exton, Pa., appointed Martin Phillips senior vice president of clinical development.

Nanogen Inc., of San Diego, appointed Robert Saltmarsh as chief financial officer.

Neose Technologies Inc., of Horsham, Pa., promoted Brian Davis to senior vice president and chief financial officer.

Neurobiological Technologies Inc., of Richmond, Calif., appointed Karl Trass director of regulatory affairs.

Neurogen Corp., of Branford, Conn., appointed Craig Saxton chairman.

NicOx SA, of Sophia-Antipolis, France, appointed Goran Ando to its board.

NovaDel Pharma Inc., of Flemington, N.J., appointed Michael Spicer chief financial officer.

Pharmacopeia Drug Discovery Inc., of Princeton, N.J., appointed Stephen Costalas executive vice president, general counsel and secretary.

Phyton Biotech Inc., of Fort Worth, Texas, appointed Allen Ruzycki director of finance and administration.

Prometheus Laboratories Inc., of San Diego, appointed Rolf Classon to its board, and Tim Sear chairman.

Velcura Therapeutics Inc., of Ann Arbor, Mich., appointed Fred Beyerlein to its board.

Neurogen Corp., of Branford, Conn., appointed Craig Saxton chairman.

Neurotech, of Lincoln, R.I., appointed Al Reaves vice president of clinical development.

No Comments